Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)
Julie E. Bauman(George Washington University), Robert L. Ferris(University of Pittsburgh), Quynh‐Thu Le(Stanford University), Ming Yao(Anhui University), A. Kulkarni(University of Pittsburgh), Gabriel Sica(Emory University), Craig B. Reeder(Mayo Clinic in Arizona), Minh Phan(University of Oklahoma Health Sciences Center), Farzan Siddiqui, Brian R. Isett(UPMC Hillman Cancer Center), Pawan Upadhyay(University of Pittsburgh), A. Chakravati(The Ohio State University), Ravindra Uppaluri(Brigham and Women's Hospital), J. Harris(American College of Radiology), S. Jujjavarapu(OSF HealthCare), J.L. Geiger(Cleveland Clinic), L. Vujanovic(University of Pittsburgh), Jie Chen(Nantong University), R. Jordan
International Journal of Radiation Oncology*Biology*Physics
September 27, 2024
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899